Immune responses to rotavirus infection and vaccination and associated correlates of protection

Journal of Infectious Diseases

Volumn 203, Issue 2, 2011, Pages 188-195

  Desselberger, Ulrich ^a   Huppertz, Hans Iko ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Prof Hess Kinderklinik   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LIVE VACCINE; NEUTRALIZING ANTIBODY; PROTEIN VP4; PROTEIN VP7; ROTAVIRUS ANTIBODY; ROTAVIRUS NONSTRUCTURAL PROTEIN 4; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ACUTE GASTROENTERITIS; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BABOON; CALF (MAMMAL); CELLULAR IMMUNITY; DIARRHEA; DISEASE COURSE; DISEASE MODEL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; LAMB; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; ROTAVIRUS INFECTION; VACCINATION; VIRUS TRANSMISSION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; CATTLE; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INFANT; MICE; RABBITS; RATS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SHEEP; SWINE;

EID: 79851471497     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq031     Document Type: Review

References (52)

1. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6.
2. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200(suppl 1):S9-15.
3. Estes MK, Kapikan AZ. Rotaviruses. In: Knipe DM, Howley PM, et al. eds. Fields virology. 5th ed. Philadelphia, PA: Wolters Kluwer Health/ LippincottWilliams&Wilkins, 2007:1917-74.
4. Blutt SE, Matson DO, Crawford SE, et al. Rotavirus antigenemia in children is associated with viremia. PLoS Med 2007; 4:e121.
5. Matthijnssens J, Ciarlet M, Heiman E, et al. Full genome-based classification of rotaviruses reveals a common origin between human Wa-Like porcine rotavirus strains and human DS-1-like and bovine rotavirus strains. J Virol 2008; 82: 3204-19. (Pubitemid 351429901)
6. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56. (Pubitemid 40070041)
7. Offit PA, Hoffenberg EJ, Santos N, Gouvea V. Rotavirus-specific humoral cellular immune response after primary, symptomatic infection. J Infect Dis 1993; 167:1436-40. (Pubitemid 23146199)
8. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Human Rotavirus Vaccine Study Group. Safety efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22. (Pubitemid 43048947)
9. Vesikari T, Matson DO, Dennehy P, et al. Rotavirus Efficacy Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33. (Pubitemid 43048948)
10. Franco MA, Greenberg HB. Immunity to rotavirus infection in mice. J Infect Dis 1999; 179(suppl 3):S466-9.
11. Rose JR, Williams MB, Rott LS, Butcher EC, Greenberg HB. Expression of the mucosal homing receptor alpha4beta7 correlates with the ability of CD8+ memory T cells to clear rotavirus infection. J Virol 1998; 72:726-30. (Pubitemid 28048892)
12. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996; 272:104-7. (Pubitemid 26110760)
13. Garaicoechea L, Olichon A, Marcoppido G, et al. Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro confer protection against diarrhea in mice. J Virol 2008; 82:9753-64.
14. Kuklin NA, Rott L, Feng N, et al. Protective intestinal anti-rotavirus B cell immunity is dependent on alpha 4 beta 7 integrin expression but does not require IgA antibody production. J Immunol 2001; 166: 1894-902. (Pubitemid 32114676)
15. Dharakul T, Rott L, Greenberg HB. Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: Virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes. J Virol 1990; 64:4375-82. (Pubitemid 20279848)
16. Offit PA, Boyle DB, Both GW, et al. Outer capsid glycoprotein vp7 is recognized by cross-reactive, rotavirus-specific, cytotoxic T lymphocytes. Virology 1991; 184:563-8.
17. Franco MA, Greenberg HB. Immunity to rotavirus in T cell deficient mice. Virology 1997; 238:169-79. (Pubitemid 28218135)
18. Brandtzaeg P, Bjerke K, Kett K, et al. Production secretion of immunoglobulins in the gastrointestinal tract. Ann Allergy 1987; 59:21-39. (Pubitemid 18014657)
19. Conner ME, Crawford SE, Barone C, Estes MK. Rotavirus vaccine administered parenterally induces protective immunity. J Virol 1993; 67:6633-41. (Pubitemid 23309130)
20. Saif LJ, Ward LA, Yuan L, Rosen BI, To TL. The gnotobiotic piglet as a model for studies of disease pathogenesis immunity to human rotaviruses. Arch Virol Suppl 1996; 12: 153-61. (Pubitemid 126446223)
21. Yuan L, Saif LJ. Induction of mucosal immune responses protection against enteric viruses: Rotavirus infection of gnotobiotic pigs as a model. Vet Immunol Immunopathol 2002; 87:147-60. (Pubitemid 34665233)
22. Hoshino Y, Saif LJ, Sereno MM, Chanock RM, Kapikian AZ. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J Virol 1988; 62:744-8. (Pubitemid 18068628)
23. Azevedo MS, Yuan L, Iosef C, et al. Magnitude of serum intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection. Clin Diagn Lab Immunol 2004; 11:12-20. (Pubitemid 38090646)
24. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8. (Pubitemid 26338732)
25. Velázquez FR. Protective effects of natural rotavirus infection. Pediatr Infect Dis J 2009; 28(Suppl 3):S54-6.
26. White LJ, Buttery J, Cooper B, Nokes DJ, Medley GF. Rotavirus within day care centres in Oxfordshire, UK: Characterization of partial immunity. J R Soc Interface 2008; 5: 1481-90.
27. Chiba S, Yokoyama T, Nakata S, et al. Protective effect of naturally acquired homotypic heterotypic rotavirus antibodies. Lancet 1986; 2:417-21. (Pubitemid 16039239)
28. Coulson BS, Grimwood K, Hudson IL, Barnes GL, Bishop RF. Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 1992; 30:1678-84.
29. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. Fecal antibody responses to symptomatic asymptomatic rotavirus infections. J Infect Dis 1993; 167:577-83. (Pubitemid 23056323)
30. Johansen K, Svensson L. Neutralization of rotavirus recognition of immunologically important epitopes on VP4 and VP7 by human IgA. Arch Virol 1997; 142:1491-8. (Pubitemid 27309171)
31. Jaimes MC, Rojas OL, Kunkel EJ, et al. Maturation trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J Virol 2004; 78:10967-76. (Pubitemid 39299637)
32. Ward RL, Clemens JD, Knowlton DR, et al. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis 1992; 166:1251-7.
33. Jaimes MC, Rojas OL, Gonzalez AM, et al. Frequencies of virus-specific CD4(+) CD8(+) T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol 2002; 76:4741-9. (Pubitemid 34441680)
34. Feng N, Burns JW, Bracy L, Greenberg HB. Comparison of mucosal systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J Virol 1994; 68:7766-73. (Pubitemid 24362663)
35. Coffin SE, Moser CA, Cohen S, Clark HF, Offit PA. Immunologic correlates of protection against rotavirus challenge after intramuscular immunization of mice. J Virol 1997; 71:7851-6. (Pubitemid 27391734)
36. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996; 272:101-4. (Pubitemid 26110759)
37. Yuan L, Kang SY, Ward LA, To TL, Saif LJ. Antibody-secreting cell responses protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus. J Virol 1998; 72:330-8. (Pubitemid 28048844)
38. Crawford SE, Estes MK, Ciarlet M, et al. Heterotypic protection induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol 1999; 73:4813-22. (Pubitemid 29246741)
39. Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: Recent developments future considerations. Nat Rev Microbiol 2007; 5:529-39. (Pubitemid 46925381)
40. Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: Current prospects future challenges. Lancet 2006; 368:323-32. (Pubitemid 44067224)
41. Vesikari T. Rotavirus vaccines. Scand J Infect Dis 2008; 40:691-5.
42. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
43. SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions recommendations. Wkly Epidemiol Rec 2009; 84:220-35.
44. Vesikari T, Karvonen AV, Majuri J, et al. Safety, efficacy, immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesushuman rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 2006; 194:370-6. (Pubitemid 44116980)
45. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:697-700.
46. SAGE. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 - conclusions recommendations. Wkly Epidemiol Rec 2009; 84:517-32.
47. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314-9.
48. Greenberg HB, Estes MK. Rotaviruses: From pathogenesis to vaccination. Gastroenterology 2009; 136:1939-51.
49. Ward R. Mechanisms of protection against rotavirus infection disease. Pediatr Infect Dis J 2009; 28(suppl 3):S57-9.
50. Centers for Disease Control and Prevention (CDC). Reduction in rotavirus after vaccine introduction-United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2009; 58:1146-9.
51. Matthijnssens J, Bilcke J, Ciarlet M, et al. Rotavirus disease vaccination: Impact on genotype diversity. Future Microbiol 2009; 4:1303-16.
52. Patel MM, Parashar UD. Assessing the effectiveness public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009; 200(suppl 1):S291-9.